Search the Newsreel

Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cadrenal Therapeutics Inc (CVKD) has an analyst rating of "Buy" based on 2 analysts, with a target price of $14.00, suggesting a 621.65% upside. The company's previous quarter EPS was -$1.43, missing the market expectation of -$1.04, and the next quarter's EPS is expected …

Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client

PNC Financial Services Group, Inc. has disclosed an 8.13% beneficial stake in Cadrenal Therapeutics (CVKD) through its subsidiary, PNC Bank, National Association. This amounts to 233,219 shares held in a fiduciary account for a client, Daniel Maltz, who maintains the rights to dividends and …

Cadrenal Therapeutics Solidifies Multi-Indication Strategy

Cadrenal Therapeutics is strengthening its multi-indication strategy for CAD-1005, focusing on both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This move follows a competitor's Phase 3 failure in CSA-AKI, highlighting the potential of Cadrenal's 12-LOX inhibitor to address a significant market …

Cadrenal Therapeutics, Inc. SEC Filing (Aug 3, 2026)

This article reports on an SEC filing (Form ARS) by Cadrenal Therapeutics, Inc. (CVKD) on August 3, 2026. The filing has a low impact and neutral sentiment according to AI-generated analysis. The article also provides recent news and other SEC filings for Cadrenal Therapeutics.

Cadrenal expands CAD-1005 development to two indications

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a dual-indication development strategy for its investigational drug CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The decision to pursue CSA-AKI follows a competitor's recent Phase 3 trial discontinuation, with Cadrenal estimating the U.S. …

CAD-1005 Phase 2 Data Show >25% Absolute Reduction in Thrombotic Events

Cadrenal Therapeutics announced a consolidated multi-indication strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), following a competitor's Phase 3 discontinuation. Late-breaking Phase 2 data revealed an absolute reduction in thrombotic events greater than 25% with a favorable …

Cadrenal Therapeutics highlights Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia, eyes CSA-AKI market

Cadrenal Therapeutics is advancing its drug CAD-1005 for heparin-induced thrombocytopenia and cardiac surgery-associated acute kidney injury, supported by positive Phase 2 data presented at ISTH 2026. The drug is positioned as a first-in-class, Phase 3-ready intravenous therapy, especially after a competitor's program failed, and …

Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure

Cadrenal Therapeutics is strategically focusing its investigational drug CAD-1005 for both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This focus comes after a competitor's clinical failure, highlighting the urgent need for treatments targeting cardio-renal injury through 12-lipoxygenase (12-LOX) inhibition. CAD-1005 aims …

CVKD|Cadrenal Therapeutics Inc|Price:2.065|Chg%:+0.095

This article provides a detailed financial overview of Cadrenal Therapeutics Inc (CVKD), including its current stock price, market capitalization, key financial figures, and recent performance trends. It highlights the company's biopharmaceutical focus, particularly on its lead investigational product tecarfarin, and includes analyst ratings, peer …

Cadrenal Therapeutics Inc (CVKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Cadrenal Therapeutics Inc (CVKD). It indicates that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also includes current stock information such as price, …

Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Cadrenal Therapeutics Inc (CVKD), including its PE, PB, and fair value. It displays current stock prices, market capitalization, and links to financial and analytical overviews. The content also lists various resources such as company information and community …

CVKD|Cadrenal Therapeutics Inc|Price:1.830|Chg%:-0.030

This article provides a detailed financial overview of Cadrenal Therapeutics Inc (CVKD), including its current stock price, market capitalization, key financial figures, and recent performance trends. It highlights the company's biopharmaceutical focus, particularly on its lead investigational product tecarfarin, and includes analyst ratings, peer …

Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cadrenal Therapeutics Inc (CVKD) focusing on various indicators and moving averages. It offers insights into the stock's support and resistance levels, and the implications of different technical signals (Buy, Sell, Neutral) from tools like MACD, RSI, and …

Cadrenal Therapeutics Market Sentiment

This article analyzes the market sentiment for Cadrenal Therapeutics (CVKD) based on analyst consensus, short interest, options flow, and insider activity. Key signals show a "Buy" consensus from analysts, 3.1% short float indicating bearish sentiment, no options flow data, and "Net Seller" insider activity …

Cadrenal Therapeutics Inc (CVKD) Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Cadrenal Therapeutics Inc (CVKD), detailing operating, investing, and financing cash flows. It also includes frequently asked questions explaining different types of cash flow and Cadrenal Therapeutics Inc's performance in these areas. Investors can …

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

Cadrenal Therapeutics has initiated a partnering process for its Cardiac Acute Critical Care Franchise, following a landmark data presentation at ISTH 2026. The company is seeking strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets, CAD-1005, frunexian, and tecarfarin. This move …

CVKD|Cadrenal Therapeutics Inc|Price:2.040|Chg%:+0.010

This article provides a detailed financial overview of Cadrenal Therapeutics Inc (CVKD), including its stock price, market capitalization, and key financial statements such as the income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings report, future forecasts, and quarterly …

Form PRE 14A CADRENAL THERAPEUTICS For: 23 July By Investing.com

The article reports on the filing of Form PRE 14A by CADRENAL THERAPEUTICS for July 23. This filing is a preliminary proxy statement, typically preceding a shareholder meeting or corporate action. The content is brief, primarily acting as an announcement of this regulatory document.

Cadrenal Therapeutics (NASDAQ: CVKD) seeks approval for 1M-share equity plan and 960K warrant shares

Cadrenal Therapeutics (NASDAQ: CVKD) is seeking stockholder approval for five proposals at its virtual annual meeting on September 24, 2026. Key proposals include electing a Class I director, ratifying their independent auditor, increasing the share reserve for its 2022 Equity Incentive Plan to 1,000,000 …

Cadrenal Therapeutics (Nasdaq:CVKD) - Stock Analysis

This report provides a comprehensive stock analysis of Cadrenal Therapeutics (CVKD), highlighting its operations as a late-stage biopharmaceutical company focused on novel therapies for immune and thrombotic conditions. The company is characterized by a small market cap, ongoing financial risks including declining earnings forecasts, …

H.C. Wainwright Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Maintains Target Price $13

H.C. Wainwright has reiterated its Buy rating for Cadrenal Therapeutics (CVKD.US) and maintained its price target at $13. This sustained positive outlook suggests the firm believes in the company's future performance and valuation. The maintained rating and target price indicate stability in the analyst's …

Cadrenal Therapeutics, Inc. SEC Filing (Jul 21, 2026)

This article reports on an SEC filing by Cadrenal Therapeutics, Inc. (CVKD), specifically a Notice of Effectiveness for an S-3 filing dated July 20, 2026. The filing indicates a "Neutral" impact and sentiment. The article also provides recent news and other SEC filings for …

Cadrenal's Phase 2 data show >25% absolute reduction in clotting events

Cadrenal Therapeutics announced the strategic alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise and has launched a structured process to seek out-licensing, portfolio monetization, or co-development partnerships for its late-stage assets including CAD-1005, frunexian, and tecarfarin. Recent Phase 2 data …

Cadrenal Therapeutics Announces Chief Medical Officer Transition

Cadrenal Therapeutics (NASDAQ: CVKD) outlines CMO Ferguson's exit deal

Cadrenal Therapeutics (NASDAQ: CVKD) has detailed the terms of its Chief Medical Officer, Dr. James J. Ferguson III's, departure. Dr. Ferguson's resignation is effective July 31, 2026, and the separation agreement includes salary payments through this date, reimbursement of approved business expenses, and company-paid …

Cadrenal Therapeutics (CVKD) Edges Lower Amid Mixed Sentiment, Holding Above Key Support - Bollinger Expansion

Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing

Cadrenal Therapeutics, Inc. has filed a notice for an exempt private offering under Rule 506(b) of Regulation D, involving options and warrants totaling $8.84 million. H.C. Wainwright & Co., LLC served as the placement agent, receiving fees and warrants for their services. The proceeds …